2025 Agenda
*All times are in EST
Apr
Fri 11
Meeting objectives and introduction
David Maloney & Frederick Locke
Welcome to the solid tumors day
Kedar Kirtane & Sarah Nikiforow
Keynote talk 1
How solid CAR-T targeting has evolved: Prasad Adusumilli
Session 1: CARs targeting cell surface proteins (part I)
Chairs: Susanne Baumeister & Kedar Kirtane
- DLL3-CAR-T for SCLC: Adam Schoenfeld
- GCC19 CAR-T therapy for refractory colorectal cancer: Overcoming challenges in expansion and persistence: Benjamin Schlechter
- Updates on logic-gated CAR T-cell therapies in pancreatic cancer: Joel Randolph Hecht
- An update on CAR T-cell therapy for breast and ovarian cancer: A long and winding road: Jennifer Specht
Panel discussion
Session 2: CARs targeting cell surface proteins (part II)
Chairs: Joel Randolph Hecht & Jennifer Specht
- CLDN6-targeted therapy with CAR-T cells +/- CARVac in relapsed germ cell tumors: Winfried Alsdorf
- hALK.CAR T cells for relapsed/refractory neuroblastoma: Susanne Baumeister
- Cell therapy advances in ovarian cancer: What we know and where we’re headed: Monica Avila
Panel discussion
Break
Session 3: T-cell engagers and TCRs
Chairs: Sarah Nikiforow & Benjamin Creelan
- Afami-Cel in Metastatic Synovial Sarcoma: The 1st genetically engineered TCR therapy approved for a solid tumor: Mihaela Druta
- Immunologic targeting of undruggable TP53 hotspot mutations through T cell receptor gene therapy: Mike Gormally
- Targeting PRAME with TCR T cells first in melanoma then beyond: Jason Luke
Panel discussion
Lunch
Session 4: TILs across solid tumors
Chairs: Allison Betof Warner & Claire Roddie
- Promising T cell targets in lung cancers: Trial updates: Benjamin Creelan
- TIL therapy for GU malignancies: Michael Poch
- Optimizing TIL therapy for melanoma & beyond: Allison Betof Warner
Panel discussion
Session 5: Novel technologies in solid tumors
Chairs: Sarah Nikiforow & Kedar Kirtane
- Talk title TBC (TanCAR-T): TBC
- Genome-edited anti-GPC3 CAR for hepatoma: Marco Davila
- Engineering myeloid cells for solid tumors and fibrosis: CARs and beyond: Michael Klichinsky
- Cell and gene therapy: Current status and future directions – An industry perspective: Will Go
- Advancing T cell therapies for solid cancers: Saul Priceman
Panel discussion
Break
Session 6: T-cell engagers and CARs in CLL
Chairs: David Maloney & Saar Gill
- Optimizing liso-cel in CLL: Sequencing and combination strategies: Mazyar Shadman
- Why bispecific antibodies may be the path forward in CLL: Alexey Danilov
Panel discussion
Session 7: CAR-T in ALL
Chairs: Claire Roddie & Saar Gill
- Obecabtagene autoleucel: What have we learned from the FELIX study?: Claire Roddie
- Talk title TBC (brexucabtagene autoleucel): Bijal Shah
- CD19/CD22 CAR-T: Noelle Frey
- SCRI‐CAR19 with CD19 T‐APC to prolong CAR T cell persistence: Rebecca Gardner
- Improving clinical activity of CD5 CART in T-ALL: Maksim Mamonkin
Panel discussion
Day 1 conclusions
Welcome reception
Apr
Sat 12
Welcome to Day 2
Sarah Nikiforow & Yi Lin
Keynote talk 2
Frontiers in CAR T-cell therapy for autoimmune diseases: David Porter
Session 8: CAR therapy for autoimmune diseases
Chairs: David Porter & Everett Meyer
- Early experience with the in vivo expanding anti-CD19 CAR-T, BMS-986353 for autoimmunity: Lazaros Lekakis
- CD19 CAR NK-cell therapy for B-cell mediated autoimmune disease: David Shook
- CAR T for dermatomyositis: Saurabh Dahiya
- Antigen-specific treatment of myasthenia: Development of rat chimeric autoantibody receptor
(CAAR) T cells to treat experimental autoimmune MuSK myasthenia: David Richman - State of the art with CAR therapy in MG: Ali Habib
Panel discussion
Session 9: How do we integrate autoimmune diseases into cell therapy centres?
Chairs: David Maloney & Sarah Nikiforow
Discussants: Frederick Locke, Everett Meyer, David Porter, Claire Roddie
Break
Session 10: Translational studies with T-cell engagers and CARs
Chairs: Yi Lin & Saar Gill
- Genomic determinants of resistance to anti BCMA and GPRC5D therapies: Francesco Maura
- Metabolic fitness in CAR-T cells from earlier in the treatment course: Ciara Freeman
- Insights into microbiome and microbial metabolites to augment CAR-T therapy: Maik Luu
Panel discussion
Keynote talk 3
Accelerating CAR T-cell therapeutics with small molecules and CRISPR2.0 gene-edits: Michael Hudecek
Lunch
Session 11: T-cell engagers for multiple myeloma
Chairs: Saad Usmani & TBC
- Cevostamab: What, how and when?: Rakesh Popat
- Teclistamab – the past was good, the future could be great!!: Tom Martin
- Talk title TBC (talquetamab): Nisha Joseph
- Multi-antigen targeting with trispecific antibodies in myeloma: JNJ-796353222: Sham Mailankody
Panel discussion
Session 12: CAR therapy for multiple myeloma
Chairs: Adam Sperling & Krina Patel
- CAR-T cells in multiple myeloma: The evolving use of cilta-cel and ide-cel: Adam Sperling
- Phase I / II summary of anito-cel for relapsed/refractory MM: Matthew Frigault
- Arlocabtagene autoleucel in relapsed refractory multiple myeloma: Susan Bal
- BCMA CAR-T clash of the Titans: Idecabtagene vicleucel and ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: Doris Hansen
Panel discussion
Break
Session 13: CAR therapy should come before T-cell engagers in multiple myeloma treatment sequencing
Chairs: Yi Lin & Doris Hansen
- For: Krina Patel
- Against: Sham Mailankody
Panel discussion
Session 14: Different approaches to CAR production in lymphoma
Chairs: David Maloney & Caron Jacobson
- Rapcabtagene autoleucel for B-cell lymphomas and the potential role of CAR-T rapid manufacturing: Julio Chavez
- Point-of-care manufacturing with Canadian-made CD19 CART, CLIC-1901: Natasha Kekre
- ATALANTA-1: A Phase 1/2 trial of GLPG5101, a fresh, stem-like, early memory CD19 CAR T-cell therapy with a 7-day vein-to-vein time, for the treatment of relapsed/refractory non-Hodgkin lymphoma: Caron Jacobson
- Interim result multicenter Phase II trial of zamtocabtagene autoleucel, an non-cryopreserved anti-CD20/anti-CD19 CAR T cell product for relapsed, refractory DLBCL: Nirav Shah
Panel discussion
Day 2 conclusions
Faculty Dinner
Apr
Sun 13
Welcome to Day 3
Caron Jacobson & Frederick Locke
Session 15: Long-term follow-up and outcomes with CARs
Chairs: David Miklos & Elizabeth Budde
- Long-term complications after CAR T-cell therapy: Michael Jain
- Beyond CRS and ICANS: Non-relapse mortality after CAR T-cell therapy: Kai Rajeski
- Catch me if you can: Lymphoma resistance to CAR T immunotherapy: Marco Ruella
- Enhancing CAR T-cell activity and persistence with CAR-enhancer therapeutics: Mohamad Rashidian
Panel discussion
Session 16: T-cell engagers and CARs in myeloid malignancies
Chairs: David Sallman & Marion Subklewe
- Back to the bench: Rethinking CAR T for AML: Marion Subklewe
- Allogeneic, off-the-shelf, CAR T cells for AML: CB-012: Jae Park
- Treatment of JMML and CMML with CLL-1 CAR-T cells +/- trametinib: Elliot Stieglitz
- Immunotherapy in CALR-mutated myeloproliferative neoplasms: Approach with caution: Andrew Kuykendall
Panel discussion
Break
Session 17: What are the current challenges with CAR T in lymphoma and how can we address them?
Chairs: Caron Jacobson & David Miklos
- Barriers: Why is CAR T-cell therapy not reaching its potential in heme malignancies?: Jason Westin
- Sequencing novel treatment options in lymphoma: Gloria Iacoboni
- Talk title TBC (perspective 3): Frederick Locke
Panel discussion
Keynote talk 4
Building a fast-paced outpatient IEC program: Elizabeth Budde
Working lunch
Session 18: T-cell engagers and CARs in lymphomas (part I)
Chairs: Tycel Phillips & Jennifer Crombie
- Update on CB-010/allogeneic anti-CD19 CAR-T cell therapy: Mehdi Hamadani
- Fixed-duration treatment with epcoritamab: Alexey Danilov
- Bispecifics in lymphoma: Moving beyond CD20 targeting: Krish Patel
Panel discussion
Session 19: T-cell engagers and CARs in lymphomas (part II)
Chairs: Jason Westin & Gloria Iacoboni
- Frontline & second-line DLBCL treatments – where are we in 2025?: Matt Lunning
- Bispecific combinations in relapsed/refractory DLBCL: Jennifer Crombie
- “Who’s on first”….Sequencing bispecifics with CAR-T in indolent lymphoma: Tycel Philips
Panel discussion
Keynote talk 5
Moving bispecifics and CAR T-cell therapies into the community setting: Tara Graff
Session 20: How to get CAR T-cell therapy into the community setting?
Chairs: Elizabeth Budde & Krish Patel
Discussants: Tara Graff, Caron Jacobson, Frederick Locke
Meeting conclusions